Nur Emillia Binte Roslan

Nur Emillia Binte Roslan

Auto-generated profile, based on publicly available information

Nur Emillia Binte Roslan

Medicine Academic Clinical Programme, SingHealth-Duke-NUS, Singapore, Singapore

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2023 in JMIR Formative Research
Verified
Journal Article
Open access
TTTze Chin Tan
Tze Chin Tan
NRNur Emillia Binte Roslan
Nur Emillia Binte Roslan
JLJames Weiquan Li
James Weiquan Li
XZXinying Zou
Xinying Zou
XCXiangmei Chen
Xiangmei Chen
ASAnindita Santosa
Anindita Santosa
Background: Chatbots have the potential to enhance health care interaction, satisfaction, and service delivery. However, data regarding their acceptance across diverse patient populations are limited. In-depth studies on the reception of chatbots by patients with chronic autoimmune inflammatory diseases are lacking, although such studies are vital for facilitating the effective integration of chatbots in rheumatology care. Objective: We aim to assess patient perceptions and acceptance of a chatbot designed for autoimmune inflammatory rheumatic diseases (AIIRDs). Methods: We administered a comprehensive survey in an outpatient setting at a top-tier rheumatology referral center. The target cohort included patients who interacted with a chatbot explicitly tailored to facilitate diagnosis and obtain information on AIIRDs. Following the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance) framework, the survey was designed to gauge the effectiveness, user acceptability, and implementation of the chatbot. Results: Between June and October 2022, we received survey responses from 200 patients, with an equal number of 100 initial consultations and 100 follow-up (FU) visits. The mean scores on a 5-point acceptability scale ranged from 4.01 (SD 0.63) to 4.41 (SD 0.54), indicating consistently high ratings across the different aspects of chatbot performance. Multivariate regression analysis indicated that having a FU visit was significantly associated with a greater willingness to reuse the chatbot for symptom determination (P=.01). Further, patients’ comfort with chatbot diagnosis increased significantly after meeting physicians (P<.001). We observed no significant differences in chatbot acceptance according to sex, education level, or diagnosis category. Conclusions: This study underscores that chatbots tailored to AIIRDs have a favorable reception. The inclination of FU patients to engage with the chatbot signifies the possible influence of past clinical encounters and physician affirmation on its use. Although further exploration is required to refine their integration, the prevalent positive perceptions suggest that chatbots have the potential to strengthen the bridge between patients and health care providers, thus enhancing the delivery of rheumatology care to various cohorts.

23 May 2023 in JMIR Preprints
Verified
Preprint
Open access
TTTze Chin Tan
Tze Chin Tan
NRNur Emillia Roslan
Nur Emillia Roslan
JLJames Weiquan Li
James Weiquan Li
XZXinying Zou
Xinying Zou
XCXiangmei Chen
Xiangmei Chen
ASAnindita Santosa
Anindita Santosa
BACKGROUND Chatbots are increasingly used in health care to enhance patient engagement, satisfaction, and cost-effectiveness. However, chatbot acceptability varies among patient populations and has not been well studied in patients with autoimmune inflammatory rheumatic disease (AIIRD). OBJECTIVE To examine the acceptability of a chatbot designed explicitly for AIIRD. METHODS A survey was conducted in an outpatient setting at a tertiary rheumatology referral center, targeting patients who interacted with a chatbot developed explicitly for diagnosing and providing information on AIIRD. Based on the RE-AIM framework, the survey assessed the chatbots’ effectiveness, acceptability, and implementation. RESULTS A total of 200 patients with rheumatological conditions participated in the survey between June and October 2022 (100 first visits and 100 follow-up visits). The study demonstrated the overall high acceptability of chatbots in rheumatology, which remained consistent across age, gender, and visit type. The subgroup analysis indicated that individuals with higher educational backgrounds tended to be more receptive to chatbots as sources of information. Participants with inflammatory arthropathies also demonstrated a higher degree of chatbot acceptability as an information source than individuals with connective tissue disease. CONCLUSIONS Our study demonstrated that the chatbot had high acceptability among patients with AIIRD, independent of patient demographics or type of visit. Acceptability is more pronounced in patients with inflammatory arthropathies and in those with higher educational levels. Health care providers can use these insights when considering the implementation of chatbots in rheumatology to improve patient care and satisfaction.